What's New: July 2026 Update TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints Availability unchanged: Retatrutide still investigational, no FDA approval until late 2027 at earliest Tirzepatide still the best available option: 22.5% weight loss, FDA-approved, available today TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program NDA timeline on track: industry estimates continue to expect Q4 2026 filing, following TRIUMPH-1's positive readout Introduction The evolution of weight loss medications has progressed rapidly from single-agonist drugs to multi-agonist approaches
In the STEP UP T2D study, dysesthesia, which includes unusual skin sensations like tingling or burning, was more frequently observed at a dose of 7.2 mg
Perez-Campos E, Mayoral L-C, Andrade G, Mayoral E-C, Huerta T, Canseco S, et al
Contrave: Contrave combines two medications, naltrexone and bupropion, which work together to affect the areas of the brain that control eating behavior and appetite
Your personalized consultation will guide you in understanding what suits your health goals most effectively
Your provider will customize your dosing schedule based on your response and tolerance
